Table 1.
A summary of blood biomarkers in diagnosing major depressive disorder in adults
Study | Category | Comparison method | Cohort (M/F), age (yr) | Biomarkers | Medicationnaive | AUC | Sensitivity/specificity (%) |
---|---|---|---|---|---|---|---|
Zhang et al. [17] (2022) | Transcriptomics | Mini-International Neuropsychiatric Interview, Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale | HC=19 (6/13), Age: 22.74 | CircularRNA–hsa_circ_0002473, hsa_circ_0079651, hsa_circ_0137187, hsa_circ_0006010, and hsa_circ_0113010 | Y | Hsa_circ_0002473=0.8619 | Hsa_circ_0002473=78.57/86.67 |
Hsa_circ_0079651=0.7112 | Hsa_circ_0079651=51.72/93.75 | ||||||
MDD=29 (8/21), Age: 22.1 | Hsa_circ_0137187=0.8190 | Hsa_circ_0137187=89.29/66.67 | |||||
Hsa_circ_0006010=0.8367 | Hsa_circ_0006010=85.71/78.57 | ||||||
Hsa_circ_0113010=0.7091 | Hsa_circ_0113010=51.72/93.75 | ||||||
Lin et al. [16] (2019) | Transcriptomics | Hamilton Depression Rating Scale | HC=125 (51/74), Age: 36.8 | mRNA–Serine racemase (SSR), phosphoserine aminotransferase 1 (PSAT1), glycine C-acetyltransferase (GCAT), glutamate decarboxylase 1 (GAD1), and neuregulin 1 (NRG1) | Y | 0.889 | 0.960/0.640 |
MDD=25 (9/16), Age: 35.6 | |||||||
Gecys et al. [15] (2022) | Transcriptomics | Mini-International Neuropsychiatric Interview, International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification | Discovery cohort: | mRNA - hsa-let-7e-5p, hsa-miR-125a-5p | N | hsa-let-7e-5p: 0.66 | - |
HC=37 (8/29), Age: 21–65 | hsa-miR-125a-5p: 0.600 | ||||||
MDD=48 (12/36), Age: 19–75 | |||||||
Validation cohort: | |||||||
HC=74 (20/54), Age: 21–68 | |||||||
MDD=84 (16/68), Age: 19–75 | |||||||
Fan et al. [14] (2014) | Transcriptomics | DSM-IV, Hamilton Depression Rating Score | HC=46 (20/26), Age: 33.35 | miRNA–miRNA-26b, miRNA-1972, miRNA-4485, miRNA-4498, miRNA-4743 | N | Combined: 0.636 | Combined: 54.4/79.0 |
MDD=81 (35/46), Age: 33.28 | |||||||
Min et al. [20] (2023) | Metabolomics | DSM-IV, Hamilton Depression Rating Score | HC=41 (21/20), Age: 25–35 | TNF-α, IL-6 | Y | TNF-α=0.733 | - |
MDD=113 (42/71), Age: 24–42 | IL-6=0.783 | ||||||
Kim et al. [19] (2021) | Metabolomics | Beck Depression Index, Hamilton Depression Rating Score | HC=50 (24/26), Age: 24.8 | IL-17, IL1β, CRP | Y | Male: IL-17=0.766 | Male: IL-17=87.0/57.1 |
Female: IL-1β=0.697 | Female: IL-1β=85.0/53.4 | ||||||
MDD=50 (23/27), Age: 24.18 | IL-6 level=0.709 | IL-6 level=51.9/84.6 | |||||
CRP=0.688 | CRP=100/38.4 | ||||||
Zhang et al. [23] (2022) | Metabolomics | DSM-IV, Hamilton Depression Rating Score, Hamilton Anxiety Rating Scale | HC=25 (0/25), Age: 18–24 | 20 Lipids* | N | 0.897 | - |
MDD=28 (0/28), Age: 30–43 | |||||||
Levada et al. [21] (2020) | Metabolomics | DSM-5 | HC=47 (20/27), Age: 37.8 | IGF-1 | N | 0.820 | 83/71 |
MDD=78 (30/480), Age: 38.2 | |||||||
Kageyama et al. [18] (2018) | Metabolomics | DSM-IV, Hamilton Depression Rating Score | Discovery: | Nervonic acid | N | - | Overall: 67.1/62.2 |
HC=19 (10/9), Age: 36.1 | |||||||
MDD=9 (3/6), Age: 39.1 | |||||||
SZ=17 (8/9), Age: 33.6 | |||||||
BD=6 (1/5), Age: 41.8 | |||||||
Validation set: | |||||||
HC=100 (46/54), Age: 49.2 | |||||||
MDD=45 (19/26), Age: 54.0 | |||||||
SZ=115 (59/56), Age: 39 | |||||||
BD=71 (37/34), Age: 45.2 | |||||||
Pan et al. [22] (2018) | Metabolomics | DSM-IV, Hamilton Depression Rating Score | Discovery set: | Dopamine, GABA, Tyramine, Kyneuramine | N | Discovery: 0.968 | Discovery: 94.1/98.0 |
HC=50 (25/25), Age: 34–36 | Validation: 0.953 | Validation: 93.9/87.5 | |||||
MDD=50 (24/26), Age: 37–39 | |||||||
Validation set: | |||||||
HC=40 (22/18), Age: 37–39 | |||||||
MDD=49 (23/26), Age: 36–39 | |||||||
BD=30 (13/17), Age: 24–46 | |||||||
Zheng et al. [24] (2016) | Metabolomics | DSM-IV | Discovery set: | Peripheral Blood Mononuclear Cells (PBMC)–top 17 discriminants† | Y | Discovery: 0.926 | |
HC=50 (22/28), Age: 39.7 | Validation: 0.870 | ||||||
MDD=50 (20/30), Age: 38.9 | |||||||
Validation set: | |||||||
HC=56 (24/32), Age: 31.4 (14.1) | |||||||
MDD=58 (19/39), Age: 39.5 (13.8) | |||||||
SZ=40 (9/31), Age: 27.5 (12.5) | |||||||
Liu et al. [31] (2016) | Metabolomics | DSM-IV, Hamilton Depression Rating Scale | Discovery set: | 17 Lipids‡ | N | 0.863 | - |
HC=60 (30/30), Age: 43.98 | |||||||
MDD=60 (30/30), Age: 42.42 | |||||||
Validation set: | |||||||
HC=52 (26/26), Age: 33.67 | |||||||
MDD=75 (40/35), Age: 36.04 | |||||||
Ghanbarirad et al. [26] (2021) | Genomics | DSM-5 | HC=100 (68/32), Age: 31.9 | Myelin Transcription Factor 1 (MYT1) | N | 0.973 | 0.96/0.85 |
MDD=100 (67/33), Age: 35.2 | |||||||
BD=100 (68/32), Age: 27.1 | |||||||
Chiou and Huang [25] (2019) | Genomics | Hamilton Depression Rating Scale | HC=290 (143/297), Age: 31.3 | BDNF | Y | Males: 0.652 | Males: 81.1/48.5 |
MDD=273 (66/207), Age: 39.4 | |||||||
Numata et al. [28] (2015) | Genomics | Hamilton Depression Rating Scale | Discovery set: | DNA Methylation of peripheral leukocytes–top 18 site discriminants | Y | - | 100/100 |
HC=19 (2/17), Age: 42.4 | |||||||
MDD=20 (2/18), Age: 44.2 | |||||||
Validation set: | |||||||
HC=12 (3/9), Age: 44.3 (10.8) | |||||||
MDD=12 (3/9), Age: 45.5 | |||||||
Karlović et al. [27] (2013) | Genomics | DSM-IV, Hamilton Depression Rating Scale | HC=142 (76/66), Age: 46.5 | BDNF | N | 0.892 | 83.9/93.0 |
MDD=122 (56/66), Age: 45.8 | |||||||
Jiang et al. [30] (2017) | Combined | DSM-IV, Hamilton Depression Rating Scale | HC=35 (19/16), Age: 56.74 | tPA, BDNF, Tropomyosin receptor kinase B, proBDNF, neurotrophin receptor p75NTR | Y | 0.977 | 88.1/92.7 |
MDD=35 (11/24), Age: 43.97 | |||||||
Bilello et al. [29] (2015) | Combined | DSM-IV, Hamilton Depression Rating Scale | HC=86 (46/40), Age: 20–72 | Alpha1 antitrypsin, apolipoprotein CIII, BDNF, cortisol, epidermal growth factor, myeloperoxidase, prolactin, resistin, soluble tumor necrosis factor alpha receptor type II | N | 0.963 | 92/93 |
MDD=68 (34/34), Age: 19–68 |
Value of age are presented as mean, mean (standard deviation), or range.
Cer(d15:1/25:2), Cer(d18:1/16:0), Cer(d18:1/24:0), Cer(d40:1), Cer(d41:1 + O), Cer(m34:0 + O), Cer(m38:2 + O) and PI(16:1), Cer(d32:4), CerG2GNAc1(d32:1), CerG2GNAc1(d36:1), CerG2GNAc1(d38:4), GM2(d34:5), GM3(t39:6), PC(18:0/16:0), PC(20:1e/18:2), PC(26:2e), PC(40:10), TG(18:1/18:2/22:4), TG(20:0/18:1/18:1);
octanoic acid, hydroxylamine, benzoic acid, γ-aminobutyric acid, homoserine, malonic acid, isoleucine, lanosterol, valine, sorbitol, creatinine, ribulose 5-phosphate, ethanolamine, malic acid, fumaric acid, γ-tocopherol and dopamine;
lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), 1-O-alkyl-2-acyl-PE (PE O), 1-O-alkyl-2-acyl-PC (PC O), sphingomyelin (SM), diacylglycerol (DG), and triacylglycerol (TG).
M, male; F, female; AUC, area under the curve; HC, healthy control; MDD, major depressive disorder; N, no; Y, yes; mRNA, messenger RNA; miRNA, microRNA; TNF, tumor necrosis factor; IL, interleukin; DSM, Diagnostic and Statistical Manual of Mental Disorders; CRP, C-reactive protein; IGF, insulin-like growth factor; SZ, schizophrenia; BD, bipolar disorder; GABA, gamma-aminobutyric acid